期刊文献+

核素骨显像联合血清前列腺特异性抗原游离水平与总量比值测定对前列腺癌骨转移诊断的临床意义 被引量:2

Clinical value of ^(99m)Tc-MDP bone imaging combined with serum FPSA/TPSA ratio for the diagnosis of bone metastasis in prostate cancer
暂未订购
导出
摘要 目的:研究99mTc-MDP(亚甲基二膦酸盐)核素骨显像结合前列腺特异性抗原游离水平与总量比值(FPSA/TPSA)测定在诊断前列腺癌及其骨转移中的价值。方法:对经病理证实并行骨显像和FPSA、TPSA检查的147例前列腺癌患者的临床及检测资料进行回顾性分析。结果:147例前列腺癌患者中,核素骨显像提示102例出现骨转移(占69.4%),其骨转移病灶"热区"数共631个,其中显示≥3个病灶者为81例(79.4%),2个病灶的15例(14.7%),1个病灶的6例(5.9%)。经随访发现,骨转移累及部位以盆骨最多(96例,占94.1%),且最早;其次是脊柱(77例,占75.5%)和肋骨(54例,占52.9%)。发生骨转移患者术前的血清TPSA、FPSA、FPSA/TPSA(F/T)分别为(99.14±58.90)μg/L、(11.10±8.22)μg/L、0.10±0.05;无骨转移患者血清TPSA、FPSA、F/T则分别为(24.32±21.91)μg/L、(4.37±3.43)μg/L、0.18±0.04;2组间差异有统计学意义(P<0.01)。血清TPSA、FPSA浓度与骨转移率呈正相关。PSA<10μg/L时,患者骨转移率为2.6%;PSA为10~20μg/L,骨转移率为10.5%;PSA为21~50μg/L,骨转移率为52.6%;PSA为51~100μg/L,骨转移率为92.7%;PSA>100μg/L时,骨转移率达100%。结论:对疑为前列腺癌的患者,特别是年龄>50岁者,更应重视核素骨显像和血清TPSA、FPSA检查,并计算F/T比值,密切注意随访。 Objective To study the importance of ^99mTc-MDP hone imaging combined with FPSA (free prostate specific antigen)/TPSA (total prostate specific antigen) ratio in the diagnosis of prostate cancer and its bone metastasis. Methods The clinical and laboratory data of 147 patients with prostate cancer confirmed by pathology and ^99mTc-MDP performed were retrospectively analyzed. Results Of the 147 patients, 102 cases (69.4%) were found to have bone metastasis with 331 "hot area" demonstrated by ^99mTc-MDP bone imaging. There were 77 cases (75.5%) had more than 3 "hot area", 15 cases (14.7%) had 2 "hot area",10 cases (9.8%) had l"hot area". Pelvis was the most frequent and the earliest site (96 cases, 94.1%) of bone metastasis, then were the spinal column (77eases,75.5%) and the ribs (54 cases, 52.9%). Serum TPSA, FPSA and FPSA/TPSA ratio in hone metastasis group were (99.14±58.90) μg/L, (11.10±8.22) μg/L, and 0.10±0.05, respectively. Those of non-bone metastasis group were (24.32±21.91) μg/L, (4.37±3.43) μg/L and 0.18±0.04, respectively. Serum FPSA and TPSA were positively correlated with the rate of bone metastasis. When PSA was less than 10 μg/L, the rate of bone metastasis was 2.6%; when PSA was from 10 μg/L to 20 μg/L, the rate of bone metastasis was 10.5%; when PSA was from 21 μg/L to 50 μg/L, the rate of bone metastasis was 52.6%; when PSA was from 51 μg/L to 100 μg/L, the rate of bone metastasis was 92.7%; and when PSA was high than 100 μg/L, the rate of bone metastasis was 100%. Conclusions Of those suspected to have prostate cancer (specially the men 〉50 years old) emphasis should he paid on radionuclide bone imaging and the measurement of FPSA and TPSA, and calculate the FPSA/FPSA ratio, and the patient should he followed cautiously. Early diagnosis and treatment are very important for the prognosis of patient.
出处 《诊断学理论与实践》 2009年第2期185-187,共3页 Journal of Diagnostics Concepts & Practice
关键词 锝放射性同位素 前列腺癌 前列腺特异抗原 骨转移 Technetium radioisotopes Prostate cancer Prostate specific antigen Bone metastasis
  • 相关文献

参考文献13

二级参考文献35

  • 1范义湘,罗荣城,李贵平,黄凯.骨显像联合碱性磷酸酶诊断159例前列腺癌骨转移[J].肿瘤学杂志,2004,10(5):340-342. 被引量:4
  • 2朱广文,张延军,杜雪梅,陶莉,解静慧,胡伟.~99Tc^m-MDP SPECT/CT骨显像诊断恶性肿瘤骨转移的价值[J].中华核医学杂志,2005,25(6):335-336. 被引量:53
  • 3韩伟明.-[J].日用化学工业,1987,(3):31-31.
  • 4姜义娟.-[J].日用化学工业,1986,(3):27-27.
  • 5裴著果.影像核医学:第2版[M].北京:人民卫生出版社,2000.213-221.
  • 6[3]WolffJM, Ittel TH, Boeckmann W, et al. Metastatic workup of patients with prostate cancer employing skeletal alkaline phosphatase [J]. Anticancer Res, 1997,17 (4B):2995-2997.
  • 7[5]Puig S, Staudenherz A, Steiner B, et al. Differential diagnosis of a typically located single or double hot spots in whole bone scaning[J]. J Nucl Med, 1998, 39:1263-1266.
  • 8[10]Reale MG, Santini D, Marchei GG, et al. Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow up of patients with breast canser [J]. Int J Biol Markers, 1995, 10(1):42-46.
  • 9谷现恩,现代前列腺疾病,1997年,118页
  • 10潘中允.前列腺癌的核素检查和治疗[A].郭应禄.前列腺增生及前列腺癌[C].北京:人民出版社,1998.188.

共引文献116

同被引文献12

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部